The Evolving Drug Safety Landscape: Implications for Pharma
A webinar outlining the implications of the changing regulatory landscape on the industry in the short to medium term — and what could be considered in developing strategies to increase the safety profile of products — is being hosted by ICON on Wednesday 9 December at 4 pm GMT. 'Politics, Regulators and Clinical Research' will feature panelists including ICON's Suzanne Gagnon, IMS Health's Nigel Burrows and Christopher-Paul Milne, associate director of the Tufts Center for the Study of Drug Development.
Senior pharma executives involved in the drug safety or/and outsourcing strategies for their organization are invited to attend the webinar, which will discuss "what the political reforms of today mean for clinical research tomorrow"; "how recently published draft regulations from the FDA (and the expected EMEA guidelines) address drug safety and what they mean for your organization"; and "what innovative strategies pharma/biotech companies can do to continue to deliver treatments in a cost effective way."
Click here to register for this event.
How Digital Medicine Can Pinpoint Dosing Regimens to Optimize Drug Efficacy and Safety